DLL3 CHO Cell Line

Catalog #

78882

$3,250 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

CHO-K1 cells expressing human delta like canonical Notch ligand 3 (DLL3) gene (accession number NM_016941.3) under the control of the cytomegalovirus (CMV) promoter. This cell line was generated by lentiviral transduction followed by puromycin selection and limited dilution. Individual clones were screened based on DLL3 expression to obtain this high-expressing cell line.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Product Data Gallery

Western Blot analysis of DLL3 protein expression in DLL3 CHO cells.

Product Info

Storage and Usage

Citations

Host Cell Line

CHO-K1 cells, Chinese Hamster Ovary, epithelial-like cells, adherent

Supplied As

Each vial contains >1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Materials Required But Not Supplied

Name	Ordering Information
Thaw Medium 3	BPS Bioscience #60186
Growth Medium 3L	BPS Bioscience #78104

Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

DLL3, also known as delta like ligand three, is a Notch ligand characterized by a DSL domain, transmembrane region, and a series of EGF repeats. Notch ligands can participate in trans-interactions (interaction with Notch receptor on a different cell) and cis interactions (interaction with Notch receptor within the same cell) to activate or inhibit Notch signaling, respectively. DLL3 exclusively functions to inhibit Notch signaling through cis inhibition. While DLL3 expression is limited in healthy tissue, high expression levels of DLL3 are found in various cancers including small cell lung cancer (SCLC), where it plays an oncogenic role. Relieving DLL3-mediated inhibition of Notch signaling may serve as a therapeutic avenue, with drugs being developed to target DLL3 as a possible lung cancer therapy (example: rovalpituzumab tesirine).

References

Chapman G, et al., 2011 Hum Mol Genet. 20(5):905-16
Ladi E, et al., 2005 J Cell Biol. 170 (6): 983–992
Kunnimalaiyaan M, et al., 2007 The oncologist. 12(5):535-42
Owen D, et al., 2019 J Hematol Oncol. 12(1): 61

Storage/Stability

Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.

Growth Media

For best results, the use of validated and optimized media from BPS Bioscience is highly recommended. Other preparations or formulations of media may result in suboptimal performance.

Media Required for Cell Culture
Thaw Medium 3 (BPS Bioscience, #60186): F-12K medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.

Growth Medium 3L (BPS Bioscience, #78104): F-12K medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 6 µg/ml of Puromycin.

Applications

Use as target cells to validate and characterize small molecule drugs directed at DLL3.
Perform CAR-T studies.

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

Cancer Therapy Target

Regulatory Status

Research Use Only